Glenmark Pharmaceuticals Launches Generic Cancer Drug in US Market

Glenmark Pharmaceuticals has announced the launch of a new generic cancer treatment, Eribulin Mesylate Injection, in the US market.

The Mumbai-based company, operating through Glenmark Pharmaceuticals Inc., USA, confirmed that the drug is equivalent to Eisai Inc.'s Halaven Injection and will begin distribution this month.

Glenmark's President & Business Head, North America, Marc Kikuchi, emphasized the company's dedication to offering affordable healthcare alternatives. The Halaven Injection market has achieved approximately USD 66.3 million in sales in the past year.

(With inputs from agencies.)